β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: Protective role of S1PR1 cardiac gene therapy

Circulation

Volumn 128, Issue 15, 2013, Pages 1612-1622

  Cannavo, Alessandro ^a,b   Rengo, Giuseppe ^a,c   Liccardo, Daniela ^a   Pagano, Gennaro ^a   Zincarelli, Carmela ^c   De Angelis, Maria Carmen ^a   Puglia, Roberto ^a   Di Pietro, Elisa ^a   Rabinowitz, Joseph E ^b   Barone, Maria Vittoria ^a   Cirillo, Plinio ^a   Trimarco, Bruno ^a   Palmer, Timothy M ^d   Ferrara, Nicola ^a,c   Koch, Walter J ^b   Leosco, Dario ^a   Rapacciuolo, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c IRCCS   (Italy)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Genetic therapy; Heart failure; Hypertrophy; Receptors, adrenergic, beta; Signal transduction

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PERFORMANCE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO GENE TRANSFER; IN VIVO STUDY; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR DOWN REGULATION; UPREGULATION;

GENETIC THERAPY; HEART FAILURE; HYPERTROPHY; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HEART FAILURE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MYOBLASTS, CARDIAC; MYOCARDIAL INFARCTION; RATS; RATS, INBRED WKY; RECEPTOR CROSS-TALK; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, LYSOSPHINGOLIPID;

EID: 84885762115     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002659     Document Type: Article

References (43)

1. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of β-arrestindependent seven transmembrane receptor signaling. Trends Biochem Sci. 2011;36:457-469
2. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007;117:2445-2458
3. Rios CD, Jordan BA, Gomes I, Devi LA. G-protein-coupled receptor dimerization: Modulation of receptor function. Pharmacol Ther. 2001;92:71-87
4. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: A functional role for receptor-receptor interaction in vivo. Circulation. 2003;108:1611-1618
5. Somvanshi RK, War SA, Chaudhari N, Qiu X, Kumar U. Receptor specific crosstalk and modulation of signaling upon heterodimerization between β1-adrenergic receptor and somatostatin receptor-5. Cell Signal. 2011;23:794-811
6. Rengo G, Lymperopoulos A, Zincarelli C, Femminella GD, Liccardo D, Pagano G, De Lucia C, Cannavo A, Gargiulo P, Ferrara N, Perrone-Filardi P, Koch WJ, Leosco D.B-Adrenergic receptor blockade restores the GRK2-mediated adrenal a2-adrenergic receptor-catecholamine production axis in heart failure. Br J Pharmacol. 2012;166:2430-40
7. Tada M, Kirchberger MA. Regulation of calcium transport by cyclic AMP: A proposed mechanism for the beta-adrenergic control of myocardial contractility. Acta Cardiol. 1975;30:231-237
8. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211
9. Rengo G, Perrone Filardi P, Femminella GD, Liccardo D, Zincarelli C, De Lucia C, Pagano G, Marsico F, Lymperopoulos A, Leosco D. Targeting β-adrenergic receptor system via G-protein coupled receptor kinase 2 (GRK2): A new paradigm for therapy and prognostic evaluation in heart failure: From bench to bedside. Circ Heart Fail. 2012;5:385-91
10. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS, Gray MO. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol. 2007;293:H3150-H3158
11. Means CK, Miyamoto S, Chun J, Brown JH. S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem. 2008;283:11954-11963
12. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, Garner HR. Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther. 2008;324:1196-1203
13. Freedman NJ, Liggett SB, Drachman DE, Pei G, Caron MG, Lefkowitz RJ. Phosphorylation and desensitization of the human beta 1-adrenergic receptor: Involvement of G protein-coupled receptor kinases and cAMPdependent protein kinase. J Biol Chem. 1995;270:17953-17961
14. Rapacciuolo A, Suvarna S, Barki-Harrington L, Luttrell LM, Cong M, Lefkowitz RJ, Rockman HA. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem. 2003;278:35403-35411
15. Watterson KR, Johnston E, Chalmers C, Pronin A, Cook SJ, Benovic JL, Palmer TM. Dual regulation of EDG1/S1P(1) receptor phosphorylation and internalization by protein kinase C and G-protein-coupled receptor kinase 2. J Biol Chem. 2002;277:5767-5777
16. Esposito G, Perrino C, Cannavo A, Schiattarella GG, Borgia F, Sannino A, Pironti G, Gargiulo G, Di Serafino L, Franzone A, Scudiero L, Grieco P, Indolfi C, Chiariello M. EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res Cardiol. 2011;106:577-589
17. Yamaguchi I, Torda T, Hirata F, Kopin IJ. Adrenoceptor desensitization after immobilization stress or repeated injection of isoproterenol. Am J Physiol. 1981;240:H691-H696
18. Krenek P, Kmecova J, Kucerova D, Bajuszova Z, Musil P, Gazova A, Ochodnicky P, Klimas J, Kyselovic J. Isoproterenol-induced heart failure in the rat is associated with nitric oxide-Dependent functional alterations of cardiac function. Eur J Heart Fail. 2009;11:140-146
19. Hwang GS, Oh KS, Koo HN, Seo HW, You KH, Lee BH. Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure. Eur J Pharmacol. 2006;540:131-138
20. Alvarez BV, Johnson DE, Sowah D, Soliman D, Light PE, Xia Y, Karmazyn M, Casey Jr. Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy. J Physiol. 2007;579(pt 1):127-145
21. Jeong K, Kwon H, Min C, Pak Y. Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts. Exp Mol Med. 2009;41:226-235
22. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation. 2009; 119:89-98
23. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol. 2011;50:785-792
24. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW 2nd, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem. 2010;285:16378-16386
25. Leosco D, Rengo G, Iaccarino G, Golino L, Marchese M, Fortunato F, Zincarelli C, Sanzari E, Ciccarelli M, Galasso G, Altobelli GG, Conti V, Matrone G, Cimini V, Ferrara N, Filippelli A, Koch WJ, Rengo F. Exercise promotes angiogenesis and improves beta-adrenergic receptor signalling in the post-ischaemic failing rat heart. Cardiovasc Res. 2008;78:385-394
26. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108-2118
27. Waeber C, Blondeau N, Salomone S. Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect. 2004;17:365-382
28. Wang S, Zhang Z, Lin X, Xu DS, Feng Y, Ding K. A polysaccharide, MDG-1, induces S1P1 and bFGF expression and augments survival and angiogenesis in the ischemic heart. Glycobiology. 2010;20:473-484
29. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) [published correction appears in J Am Coll Cardiol. 2006;47:1503-1505]. J Am Coll Cardiol. 2005;46: E1-E82
30. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41:233-243
31. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823
32. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in β-adrenergic neuroeffector mechanism in ischaemic versus idiopathic cardiomyopathy. Circulation. 1991;84:1024-1039
33. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992;340:88-92
34. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254
35. Noor N, Patel CB, Rockman HA. β-Arrestin: A signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol. 2011;51:534-541
36. Rapacciuolo A, Rockman HA. Role of β-adrenoceptor desensitization in heart failure. Cardiovasc Drug Rev. 2000;17:384-394
37. Esposito G, Rapacciuolo A, Naga Prasad SV, Rockman HA. Cardiac hypertrophy: Role of G protein-coupled receptors. J Card Fail. 2002;8(suppl):S409-S414
38. Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A, Berrebi-Bertrand I. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol. 2001;33:1589-1606
39. Yeh CC, Li H, Malhotra D, Huang MC, Zhu BQ, Goetzl EJ, Vessey DA, Karliner JS, Mann MJ. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;296:H1193-H1199
40. Vessey DA, Li L, Kelley M, Karliner JS. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun. 2008;375:425-429
41. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002;34:509-518
42. Jin ZQ, Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO, Goetzl EJ, Karliner JS, Gray MO. Cardioprotection mediated by sphingosine- 1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol. 2002;282:H1970-H1977
43. Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE. Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci. 2010;3:81-89